-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Shanton Pharma, a clinical-stage biotechnology company that has developed a breakthrough treatment for patients with refractory/tophi gout, announced the launch of the RID GOUT study, a Phase IIb study
of Shanton's investigational drug, SAP-001, on January 9.
"Gout is a chronic accumulation disease with serious complications associated with the accumulation of uric acid in joints and other tissues and organs
.
There is a clear unmet medical need, and patients have few options for treating chronic refractory/tophi gout," said Dr.
Huang Zhenhua, Chairman of Shanton Pharma, "Shanton's experienced team and the good safety and efficacy of SAP-001 are well positioned to provide better solutions for this group of patients with unmet medical needs, thereby achieving effective tophi lysis and long-term normalization of blood uric acid levels.
"